Navigation Links
Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
Date:11/11/2008

t, Poly IC-Poly Arginine

(Poly-ICR), at the World Vaccine Congress 2008 in Lyon, France.

Study results demonstrated Poly-ICR to be a potent vaccine adjuvant

targeting the Toll-like Receptor 3 (TLR3) pathway. Data showed that

Poly-ICR, in combination with model antigens, elicits strong anti-

target antibody and CD8 T-cell immune responses. These findings

demonstrate the versatility of Poly-ICR, suggesting that the

compound may possess broad potential for use in both therapeutic and

prophylactic vaccines.

o The company recently announced that it has nominated Hsp 6/11 as a

development candidate targeting the treatment of genital warts (GW)

and recurrent respiratory papillomatosis (RRP), a disease in which

benign tumors grow on the larynx, vocal cords and trachea.

Combined, GW and RRP affect more than 2.5 million people worldwide

and represent an estimated global market potential of more than $1

billion. There are currently no approved cures for either

condition. Early preclinical data suggest that Hsp 6/11 has the

ability to elicit strong T-cell responses against HPV types 6 and 11

target antigens.

"During the quarter, Nventa announced positive clinical results for our lead candidate, HspE7, presented important and compelling findings on the potency of our proprietary adjuvant, and expanded our pipeline by nominating Hsp 6/11 for further development," said Gregory M. McKee, president and chief executive officer at Nventa. "We are also very enthusiastic about our Material Transfer Agreements to leading vaccine developers in the U.S. and abroad who are evaluating Poly-ICR for potential incorporation into a wide range of vaccine products. Nventa remains committed to the value in our core assets and we are working aggressively with multiple parties to explore opportuni
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... ... detection and quantification of partially hydrolyzed gluten in foods, has been accepted by ... the method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” ...
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, ... as Sales & Marketing Director. , With more than 25 years of ... for reinforcing Tronics’ business development activities worldwide. He brings to the company his ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes ... Reported sales were $697 million compared to $701 million ... by 8%, and changes in foreign currency exchange rates ... 1%. , By business unit, organic sales growth ... in SAFC Commercial. , Reported diluted EPS was ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Focus on Business, NEW YORK, March 4 ... of ExaStore Clustered NAS 2008,designed to meet the most ... environments., "Organizations have seen exponential growth in data ... Arnon Gat, Exanet,President & CEO. "ExaStore 2008 has been ...
... MINO(R) Set to Dramatically Improve Airway Inflammatory Disease ... through Personalized Inflammation Control, NEW PROVIDENCE, N.J., March ... NIOX MINO (http://www.nioxmino.com ), a,hand- held point-of-care device ... by the U.S. Food and Drug Administration (FDA).,Physicians in ...
... - Enerkem today announced progress on,the construction of ... ethanol., The Enerkem plant in Westbury, Canada ... world to make cellulosic ethanol at an industrial ... ethanol from creosoted urban wood,(end-of-life cycle power poles). ...
Cached Biology Technology:Exanet Announces ExaStore 2008 Clustered NAS System 2FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 2FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 3FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma 4Enerkem announces progress on construction of Canada's first cellulosic ethanol plant 2
(Date:7/31/2015)... Conn. , Jul. 31, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies such ... by introducing a common, uniform way to manage all ...
(Date:7/27/2015)... ANGELES , July 27, 2015   ... evidence- and experience-based clinical improvement solutions, today announced ... solution is now available on Android smartphones and ... inpatient and post-care organizations can use ZynxCarebook to ... same patient,s condition, streamline care transitions to other ...
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... 2012 By analyzing the hundreds of metabolic products ... Center for Epigenetics & Metabolism have discovered that circadian ... the production of such key building blocks as amino ... 600 liver-originated metabolites, which are the chemical substances created ...
... Geology doesn,t stop at borders. Mexico, the U.S., and ... environmental and resource problems. In an effort to promote ... Center of Geoscience and the Institute of Geology of ... de Mxico; UNAM) are hosting the 108th meeting of ...
... scientist has methodically demonstrated that a face,s features or constituents ... key to recognizing a person. Their study, which goes ... this month in Psychological Science . In addition ... results may help scientists understand rare facial recognition disorders. ...
Cached Biology News:Circadian rhythms have profound influence on metabolic output, UCI study reveals 2Geological Society of America Cordilleran section meets in the heart of Mexico 2Geological Society of America Cordilleran section meets in the heart of Mexico 3Geological Society of America Cordilleran section meets in the heart of Mexico 4New research about facial recognition turns common wisdom on its head 2
Complete cell culture media with cytokines...
... normal multiple tissue panels are designed ... of genes or proteins of interest ... mounted on positively charged glass slides. ... in the identical format, and cDNA ...
8 different frozen tissues are mounted on positively charged glass slides...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
Biology Products: